Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ARMS2	387715	BEVACIZUMAB	CHEMBL1201583		PharmGKB

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ARMS2	rs10490924	TT	bevacizumab	efficacy	yes	as determined by lower changes in visual acuity score. TG heterozygotes seemed to have higher changes than GG homozygotes. This variant was not associated with significant difference in central retinal thickness or max. lesion thickness.	Genotype TT is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.	22594510	827920004
ARMS2	rs10490924	GT	ranibizumab	efficacy	no	Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections.	Genotype GT is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype TT.	22840423	981755229
ARMS2	rs10490924	GG	ranibizumab	efficacy	no	Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections.	Genotype GG is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype TT.	22840423	981755213
ARMS2	rs10490924	GT + TT	bevacizumab	efficacy	no	No significant difference in change in central macular thickness (measured by optical coherence tomography) were seen between any the genotypes, over either 6 or 12 months of treatment.	Genotypes GT + TT are not associated with response to bevacizumab in people with Macular Degeneration as compared to genotype GG.	23204795	1183699677
ARMS2	rs10490924	GT + TT	bevacizumab	dosage	no	No significant differences in the average number of additional bevacizumab injections (after the initial three intravitreal injections), were seen between any of the genotypes.	Genotypes GT + TT are not associated with dose of bevacizumab in people with Macular Degeneration as compared to genotype GG.	23204795	1183699689
ARMS2	rs10490924	GT + TT	bevacizumab	efficacy	yes	Patients with the GT and TT genotype had greater improvements in visual acuity (using a Snellen eye exam chart then converted to a logarithm of the minimal angle of resolution value) between baseline and 6 months of treatment, as compared to those with the GG genotype. Patients with the TT genotype had the greatest visual acuity improvement, followed by the GT and then the GG genotype. No significant differences were seen when considering improvement over 12 months of treatment.	Genotypes GT + TT are associated with increased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.	23204795	1183699670
ARMS2	rs10490924	TT	bevacizumab	efficacy	no	No significant difference in genotype frequencies was seen between patients classified as non-responders, and those classified as responders or partial responders. Responder status was determined by optical coherence tomography; please refer to the paper directly for definitions of responder, partial responder, and non-responder.	Genotype TT is not associated with response to bevacizumab in people with Macular Degeneration as compared to genotypes GG + GT.	23584701	1184166137
ARMS2	rs10490924	T	bevacizumab	efficacy	no	Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 3 tests.	Allele T is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele G.	24070809	1184165242
ARMS2	rs10490924	G	ranibizumab	efficacy	no	Patients underwent 5 monthly injections. Good response at month 5 was defined as best-corrected visual acuity improvement of >= 8 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline. Bonferroni correction for multiple testing.	Allele G is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.	23842101	1184510406
ARMS2	rs10490924	TT	photodynamic therapy	efficacy	no	Specifically age-related macular degeneration patients who failed VEGF inhibitor therapy.	Genotype TT is not associated with response to photodynamic therapy in people with Macular Degeneration as compared to genotype GG.	26780119	1447680610
ARMS2	rs10490924	GG + GT	photodynamic therapy	efficacy	no	While there was no significant association between genotype and response to PDT, there was a trend between visual acuity post treatment and genotype. Visual acuity post-PDT declined 1.0 line for the TT genotype, 2.1 lines for the GT genotype and 4.1 lines for the GG genotype. This is interesting because, while it is not statistically significant (P=0.08), the allele that puts patients at higher risk of developing age-related macular degeneration (allele T) seems to also confer a better treatment outcome.	Genotypes GG + GT are not associated with response to photodynamic therapy in people with Macular Degeneration as compared to genotype TT.	18292785	981478575
ARMS2	rs10490924	TT	bevacizumab	efficacy	no	No significant differences in mean visual acuity (units = letters), mean visual acuity change from baseline (units = letters), >= 15-letter increase from baseline (%), mean number of injections, retinal thickness (%, units = um), mean change in total foveal thickness from baseline (units = um), dry on optical coherence tomography (%), leakage on fluorescein angiography (%) or mean change in lesion size from baseline (units = disc area) after 1 year of treatment were seen between genotypes. p <= 0.01 was considered statistically significant to adjust for multiple comparisons.	Genotype TT is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes GG + GT.	23337555	1183491577
ARMS2	rs10490924	G	ranibizumab	efficacy	no	Age-related macular degeneration. No significant differences in best-corrected visual acuity (BCVA) changes or central subfield macular thickness (CSMT) changes were seen between baseline and 3 or 6 months of treatment between any of the genotypes.	Allele G is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.	23559864	1183682045